CHF17.36
3.88% yesterday
SIX Swiss Exchange, Apr 04, 05:30 pm CET
ISIN
CH0325814116
Symbol
KURN
Sector
Industry

Kuros Biosciences Target price 2025 - Analyst rating & recommendation

Kuros Biosciences Classifications & Recommendation:

Buy
100%

Kuros Biosciences Price Target

Target Price CHF27.00
Price CHF17.36
Potential
Number of Estimates 1
1 Analyst has issued a Kuros Biosciences price target 2026. The average Kuros Biosciences target price is CHF27.00. This is higher than the current stock price.
A rating was issued by 1 analysts: 1 Analysts recommend Kuros Biosciences to buy, 0 to hold and 0 to sell.
Analysts don't have a crystal ball either, but they do represent the opinion of the market quite well. You should not take the price potential and the ratings as a recommendation to act. Rather, they serve as an additional building block for your own opinion or stock analysis.
Analyst Estimates: Analysts believe that the Kuros Biosciences stock has an average upside potential 2026 of . Most analysts recommend the Kuros Biosciences stock at Purchase.

Sales and Margin forecast 2025, 2026 & 2027

Create a premium account to unlock analyst estimates. Learn more

Dec '24 2025
Estimates
Revenue Million CHF 75.56 124.00
125.15% 64.11%
EBITDA Margin 3.40% 12.74%
144.24% 274.57%

1 Analyst has issued a sales forecast Kuros Biosciences 2025 . The average Kuros Biosciences sales estimate is

CHF124m
Unlock
. This is
64.11% higher
Unlock
than the revenue of the last 12 months(TTM). The highest sales forecast is
CHF124m 64.11%
Unlock
, the lowest is
CHF124m 64.11%
Unlock
.

This results in the following potential growth metrics:

Revenue Estimates

2024 CHF75.6m 125.15%
2025
CHF124m 64.11%
Unlock
2026
CHF169m 36.05%
Unlock
2027
CHF214m 26.97%
Unlock

1 Analyst has issued an EBITDA forecast Kuros Biosciences 2025 . The average Kuros Biosciences EBITDA estimate is

CHF15.8m
Unlock
. This is
514.79% higher
Unlock
than the EBITDA of the last 12 months(TTM). The highest EBITDA forecast is
CHF15.8m 514.79%
Unlock
, the lowest is
CHF15.8m 514.79%
Unlock
.

This results in the following potential growth metrics and future EBITDA Margins:

EBITDA Estimates

2024 CHF2.6m 199.61%
2025
CHF15.8m 514.79%
Unlock
2026
CHF27.6m 74.68%
Unlock
2027
CHF42.3m 53.26%
Unlock

EBITDA Margin

2024 3.40% 144.24%
2025
12.74% 274.57%
Unlock
2026
16.36% 28.41%
Unlock
2027
19.75% 20.72%
Unlock

Earnings per share, P/E ratio and EV/sales Estimates 2025, 2026 & 2027

Create a premium account to unlock analyst estimates. Learn more

Dec '24 2025
Estimates
EV/Sales 5.21

Based on analysts' sales estimates for 2025, the Kuros Biosciences stock is valued at an EV/Sales of

and an P/S ratio of .

This results in the following potential growth metrics and future valuations:

EV/Sales

Current 8.55 33.80%
2025
5.21 39.08%
Unlock
2026
3.83 26.50%
Unlock
2027
3.02 21.24%
Unlock

P/S ratio

Current 8.72 31.17%
2025
5.31 39.06%
Unlock
2026
3.91 26.50%
Unlock
2027
3.08 21.24%
Unlock

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today